Introduction
Betulinic acid (BA) is a natural agent isolated from birch trees, which was first described to induce apoptosis in neuroectodermal tumor cells. 1 Later on, various other solid tumor cells like colon and lung cancer cells were found to be sensitive towards apoptosis induction by BA.
2,3 BA does not induce apoptosis in normal human cells and is untoxic in animal studies in concentrations up to 100 mg/kg body weight. 1, 2 In an animal model with human ovarian carcinoma tumor cells, therapy using BA enhanced survival time by 37% compared to untreated controls. 2 Therefore, BA might represent a future cytotoxic drug to treat solid tumors.
In neuroectodermal tumor cells, BA activates mitochondria which then release cytochrome c. Overexpression of Bcl-2, Bcl-XL or treatment with bongkrekic acid, a stabilizer of the permeability transition pore complex, inhibits cytochrome c release and induction of apoptosis. 4, 5 Subsequent formation of the apoptosome leads to activation of caspases and nuclear fragmentation. 6 Furthermore, formation of reactive oxygen species, protein neosynthesis and topoisomerases I and IIa are involved in apoptosis induction, but BA signals apoptosis independently of p53 and death receptors. 2, 4, 5, 7, 8 As the effect of BA on hematologic malignancies is not yet known, we examined BA on acute leukemia tumor cells.
Materials and methods

Materials
BA (Sigma, Deisenhofen, Germany) was dissolved in DMSO (4 mg/ml) at 371C. Methotrexate, zVAD and zLEHD were obtained from Calbiochem (San Diego, CA, USA), vincristine from USPC Inc (Rockville, MD, USA), bongkrekic acid from Biomol (Plymouth Meeting, PA, USA), 4-hydroperoxycyclophosphamide from Baxter oncology GmbH (Frankfurt, Germany); all other reagents from Sigma. For Western Blot the following antibodies were used: anti a-Tubulin antibody (Oncogene, San Diego, CA, USA), anti-Bid antibody (Trevigen, Gaithersburg, MD, USA), anti-cytochrome c antibody, anti-caspase-3 antibody, anti-caspase-9 antibody (Pharmingen, Heidelberg, Germany), anti-caspase-10 antibody (MBL International, Watertown, MA, USA), anti-Smac antibody (Upstate Biotechnologies, Lake Placid, NY, USA) and anti-COX4 antibody (Clontech, Palo Alto, CA, USA). Anti-caspase-8 antibody was a kind gift by M Peter.
Cell culture
Cell lines were maintained in RPMI 1640 (GIBCO, Life Technologies, Karlsruhe, Germany) supplemented with 10% FCS (Seromed, Berlin, Germany), 2 mM L-glutamine (GIBCO) and 1 mM HEPES buffer solution (GIBCO). Drug-resistant cell lines were generated as depicted in Figure 3a . FADD-DN, caspase-8 À/À, Bcl-2 overexpressing, RIP negative, IKKg negative and IkBa 2ND4 JURKAT cells are described elsewhere.
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Primary leukemia samples
Primary acute leukemia cells were obtained at initial diagnosis or at relapse before antitumor treatment by bone marrow puncture from 47 children treated at the Dr von Haunersches Kinderspital, Munich in January 2001 to January 2003. Cells were isolated using Ficoll Isopaque (Amersham, Uppsala, Sweden) and stimulated directly after resuspension in RPMI containing 20% FCS. Apoptosis was measured by forwardside scatter analysis using FACscan after 24 h, if spontaneous apoptosis was X40%, otherwise after 48 h. Seven samples were excluded from the analysis, because DMSO (in which BA is dissolved) induced X5% specific apoptosis. The complete stimulation with all 11 stimuli was performed on 25 samples, which were used for comparison of BA with cytotoxic drugs (Figures 2a-c and 3d ). In the remaining samples, testing was incomplete due to small sample volume.
Apoptosis assay
Cell line experiments were performed in the presence of low FCS. For this purpose, FCS containing medium was replaced by FCS-free medium without additional washing. Cell viability of untreated cells was 490% after 24 h. DMSO controls were carried out for all experimental settings. Apoptosis was measured by forwardside scatter analysis using FACscan (Becton Dickinson, Heidelberg, Germany). Specific apoptosis was calculated as ((BA-induced apoptosisÀspontaneous apoptosis) divided by (100Àspontaneous apoptosis) Â 100). For cell lines one representative out of three independent experiments is shown. Data are presented as the mean of duplicates. Standard deviation was o5% for cell line experiments.
Isolation of mitochondria and Western blot
Mitochondrial fractions were prepared using the ApoAlert Cell Fractionation kit (Clontech) so that no cytosolic contamination was detected by Western blot staining of a-tubulin. Western blot was performed as described. 18 
Statistical analysis
One-way ANOVA, paired t-test, t-test, rank-sum test or Spearman's rank order correlation test was applied. Statistical significance was accepted with Po0.05.
Results
BA-induced apoptosis in primary leukemia cells and leukemia cell lines
Primary tumor cells of 40 children with untreated acute leukemia were tested for BA-induced apoptosis in vitro. BA at 10 mg/ml induced at least 10% specific apoptosis in 65% (26/40) of samples and more than 50% specific apoptosis in 30% (12/ 40) of samples with a median of 25% (25th quartile: 0%, 75th quartile: 52%) (Figure 1a) . In two primary samples, 3 mg/ml BA Primary leukemia cells of 40 children with acute leukemia were tested for BA-induced apoptosis in vitro (see Figure 1a ) and were correlated to clinical data concerning age, gender, type of leukemia and risk stratification. One-way ANOVA on ranks was applied to test for statistical significance. No statistically significant differences were found between the groups.
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was sufficient to induce more than 50% specific apoptosis. BAinduced apoptosis was independent of patients age, sex, type of leukemia or risk stratification (Table 1) .
When BA was applied on leukemia cell lines, JURKAT T-cell leukemia cells underwent rapid dose-and time-dependent apoptosis, resulting in 75% dead cells within 6 h by 10 mg/ml BA (Figure 1b) . BA preparations of different origin (Alexis Corporation, BioService Halle) yielded equal results (data not shown). All cell lines tested including the T-cell leukemia cell lines SKW6, HUT 78 and CEM, the B-cell lines BJAB, NALM6 and BOE and the myeloid cell line HL-60 showed sensitivity towards BA-induced apoptosis (Figure 1c) . The form of cell death induced by BA was apoptotic as it was accompanied by phosphatidylserine exposure on the cell surface followed by an increase in sub-G1 peak of DNA fragmentation (Figure 1d) . Similar results were found in three primary samples (data not shown).
Apoptosis induction by BA compared to cytotoxic drugs
On primary leukemia cells 10 cytotoxic drugs were tested in parallel to BA, which participated in current treatment protocols for acute leukemia in children. Overall, wide differences in sensitivity to different stimuli were found both within each sample and between the samples (Table 2 ). In median, BA was more potent than 9/10 cytotoxic drugs tested (Figure 2a) . In contrast, 6-thioguanine and methotrexate showed extremely poor apoptosis induction in vitro. In one sample of c-ALL cells at first relapse, 9/10 cytotoxic drugs were unable to induce any cell death, while BA induced 93% specific apoptosis (Table 2) . No correlation was found between spontaneous apoptosis and apoptosis-induction by any cytotoxic drug including BA (Table 2 and data not shown).
Most cytotoxic drugs induced higher apoptosis in samples obtained at initial diagnosis (n ¼ 20) compared to samples obtained at relapse (n ¼ 5) (Figure 2b ). In contrast, BA was the most effective agent in the case of relapse.
Cells of a 2-year-old girl with T-ALL were stimulated with BA, dexamethasone and doxorubicine both at initial diagnosis and at relapse in vitro. In vivo, the girl had received dexamethasone and doxorubicine according to standard treatment protocols, but not BA. At relapse, these cells had acquired complete resistance to both cytotoxic drugs, but remained sensitive to BA (Figure 2c ). Thus in this primary sample sensitivity for BA-induced apoptosis 29  87  92  93  100  64  96  96  91  96  66  19  13  f  AML  2nd relapse  45  85  84  91  86  63  99  87  97  92  94  12  3  f  c-ALL  Diagnosis  45  100  95  100  100  37  98  100  73  98  91  6  2  f  c-ALL  Diagnosis  46  98  100  68  100  27  100  86  100  100  84  16  2  f  c-ALL  Diagnosis  48  98  100  100  100  94  100  100  100  100  82  9  3  m  c-ALL  Diagnosis  50  94  94  100  90  72  100  90  96  88  97  18  1  m  AML  1st relapse  51  90  71  91  100  64  100  100  100  100  53  15  15  m  T-ALL  Diagnosis  53  100  91  53  21  9  100  29  74  99  12  14  2  f  c-ALL  Diagnosis  56  100  100  100  100  78  100  100  100  100  90  5  3  m  pre-B-ALL Diagnosis  57  100  100  94  82  54  100  76  100  100  66  11  2  f  c-ALL  Diagnosis  60  95  88  96  78  91  99  86  100  97  84  24  9  f  c-ALL  1st relapse  78  100  96  100  95  96  100  83  100  100  100  17  2  f  c-ALL  Diagnosis  85  94  92  95  95  92  100  100  98  100  100  31  7  m  AML  Diagnosis  92  98  87  96  93  39  100  100  91  100  89  27  4  m  pre-B-ALL Diagnosis  95  96  100  51  71  24  100  71  96  53  75  25  2  f  c-ALL  Diagnosis  100  98  83  87  86  78  100  85  100  94  86  40  6  m  c-ALL  1st relapse  100  95  86  96  92  50  97  95  90  98  60  30  5  m  c-ALL  Diagnosis  100  100  89  100  100  79  100  100  100  100  79  37  11 Annotations as in Table 1 . Primary leukemia cells of 25 of the 40 children depicted in Figure 1a and comprised in Table 1 were stimulated with BA (10 mg/ml) or with cytarabine (AraC; 1 mM), asparaginase (Asp; 1 U/ml), 4-hydroperoxycyclophosphamide (Cyclo; 1 mM), dexamethasone (Dexa; 10 -6 M), doxorubicine (Doxo; 300 ng/ml), methotrexate (MTX; 10 mM), prednisolone (Pred; 10 -5 M), 6-thioguanine (6-TG; 3 mM), vincristine (VCR; 30 mM) or etoposide (VP-16; 3 mM). Apoptosis was measured by FSC after 24 or 48 h (see Materials and methods). Specific survival (%) is depicted for each sample and cytotoxic drug as mean of duplicates. 
Lack of crossresistances between BA and cytotoxic drugs
To test for crossresistances between BA and cytotoxic drugs, drug-resistant JURKAT and CEM cell lines were established. Parental T-cell leukemia cells were incubated with increasing concentrations of dexamethasone, doxorubicine, methotrexate or vincristine over 12 months so that derivative cells resisted up to a 100-fold higher concentration of the drug than parental cells (Figure 3a) . Consistent with previous results, 4 BA-induced apoptosis did not differ in parental and derivative cell lines apart from methotrexate-resistant JURKAT cells, which showed significantly enhanced apoptosis sensitivity towards BA-induced apoptosis (Figure 3b and c) . In primary samples, apoptosis induction by BA did not correlate to apoptosis induction by doxorubicine (Figure 3d) or any other cytotoxic drug tested (data not shown).
Intracellular signaling pathway of BA-induced apoptosis
In neuroectodermal tumor cells, BA treatment leads to the release of cytochrome c from the mitochondria and activation of downstream caspases. 6 When isolated mitochondria of JURKAT (Figure 4a) , CEM or SKW6 (data not shown) cells were stimulated with BA, cytochrome c and Smac were released into the supernatant within 30 min, which was inhibited by bongkrekic acid, a stabilizer of the mitochondrial permeability transition pore. 15 JURKAT cells stimulated with BA showed activation of caspase-3, -8, -9 and -10 and cleavage of Bid (Figure 4b ), but not XIAP (data not shown). Release of Table 2 were correlated to BA (10 mg/ml) and doxorubicine (doxo, 300 ng/ml) induced apoptosis. Spearman's rank correlation coefficient yielded P40.05. cytochrome c into the cytosol was further confirmed in intact cells using a conformation-specific antibody (data not shown). Overexpression of Bcl-2, application of the irreversible broad spectrum caspase inhibitor zVAD-fmk or the reversible Caspase-9-specific inhibitor zLEHD reduced BA-induced apoptosis by 65% (Figure 4c ). Neither the loss of RIP, FADD or caspase-8 nor the inhibition of NFkB activation in cells negative for IKKg or overexpressing a mutant, dysfunctional form of IkBa influenced induction of apoptosis by BA (Figure 4d ).
Discussion
Initially, apoptosis induction by BA was thought to be restricted to neuroectodermal tumor cells. 1, 4 Later, additional solid tumor cells turned out to be sensitive towards BA-induced apoptosis in vitro and in vivo. 2, 3 Our data further extended the spectrum of BA-sensitive tumor cells to hematological malignancies, as primary acute leukemia cells and leukemia cell lines were found to be sensitive to BA-induced apoptosis. Thus, a broad spectrum of tumor cells responds to BA treatment and BA represents an interesting future drug for the treatment of malignancies of different origin.
Nevertheless, leukemia cell lines are less sensitive towards apoptosis induction by BA than neuroectodermal tumor cell lines, and were therefore initially thought to be relatively resistant towards BA. In the experiments with leukemia cell lines presented here, stimulation with BA was performed at low FCS to increase apoptosis sensitivity (see Materials and methods). When JURKAT cells were stimulated with BA 10 mg/ml in a medium containing 10% FCS, apoptosis induction was 27% compared to 94% in CADO neuroblastoma cells. The LC 50 of BA was seven times higher in JURKAT T-cell leukemia cells than in CADO neuroblastoma cells (Figure 1b , and data not shown).
Primary cells, which were tested in the presence of FCS, showed higher sensitivity towards BA than JURKAT T-cell leukemia cells (Figure 1a and b) and the LC 50 of 2/40 samples was even lower than the LC 50 of the CADO neuroblastoma cell line.
As no plasma concentration is yet known for BA, 10 mg/ml was used for comparison, because this concentration was found to be nontoxic to normal human cells in vitro and might well be achieved after application of 100 mg/kg body weight ( ¼ 100 mg/ ml), which was found untoxic in animal trials.
1,2 Cytotoxic drugs were used at concentrations present in patients plasma during anticancer treatment. [16] [17] [18] [19] [20] [21] To validate this comparison, it remains to be determined whether 10 mg/ml represents a feasible plasma concentration for BA in humans.
Intracellular signaling of BA-induced apoptosis is similar in leukemia and in neuroectodermal tumor cells, and involves activation of mitochondria and downstream caspases, but 13 or RIP 12 or overexpressing (overexpr.) dominant-negative FADD (FADD-DN) 9 or dominant-negative IkBa (IkBa-DN) 14 were stimulated with BA (10 mg/ml) for 12 h. Apoptosis was measured by FSC. NS ¼ statistically not significant, ANOVA.
bypasses death receptors. We show for the first time that stimulation of isolated mitochondria by BA is followed by the release of Smac from the mitochondria in parallel to cytochrome c. As BA bypasses death receptors, this might explain the lack of crossresistance between BA and, for example, doxorubicine, which was shown to use death receptors for apoptosis signaling in leukemia cells. 22 Marked differences might exist between BA and cytotoxic drugs in intracellular apoptosis signaling, as both in primary samples and cell lines no crossresistances were found between BA and all cytotoxic drugs tested.
Of special interest is the fact that BA might be able to induce apoptosis in cells otherwise difficult to treat. In contrast to cytotoxic drugs, BA induces at least as much apoptosis in cells obtained at relapse than it does in cells at initial diagnosis. This finding might be due to the fact that cells in vivo were exposed to cytotoxic drugs, but not to BA. Second, sensitivity for BA is independent of resistance to cytotoxic drugs so that BA might still be capable to induce apoptosis in leukemia cells with acquired apoptosis resistance against cytotoxic drugs. Third and in contrast to most cytotoxic drugs tested, BA induces apoptosis as efficient in cells of patients from the high-risk group as it does in cells of standard risk patients. Taken together, BA might represent a potent apoptosis-inducing agent in leukemia cells and should be evaluated as a potential therapeutic to treat acute leukemia.
